Scarica l'app Stockscreener
1.27
2.31%
-0.03
Dopo l'orario di chiusura:
1.27
Precedente Chiudi:
$1.30
Aprire:
$1.31
Volume 24 ore:
65,886
Relative Volume:
0.05
Capitalizzazione di mercato:
$4.23M
Reddito:
$35.75M
Utile/perdita netta:
$11.57M
Rapporto P/E:
-0.3336
EPS:
-3.8069
Flusso di cassa netto:
$-26.25M
1 W Prestazione:
-19.11%
1M Prestazione:
-33.16%
6M Prestazione:
-38.65%
1 anno Prestazione:
-84.46%
Intervallo 1D:
$1.25
$1.3476
Intervallo di 1 settimana:
$1.25
$1.583
Portata 52W:
$1.06
$8.75
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Confronta RDHL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.27 | 4.33M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-08-31 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-11 | Iniziato | BTIG Research | Buy |
| 2019-07-12 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Iniziato | Nomura | Buy |
| 2017-10-06 | Iniziato | Seaport Global Securities | Buy |
| 2017-10-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-24 | Reiterato | FBR & Co. | Outperform |
| 2016-07-27 | Reiterato | FBR Capital | Outperform |
| 2015-09-29 | Iniziato | Nomura | Buy |
| 2015-07-29 | Reiterato | ROTH Capital | Buy |
| 2015-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-15 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Redhill Biopharma Ltd Adr Borsa (RDHL) Ultime notizie
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com India
RedHill Biopharma to appeal Nasdaq compliance notice By Investing.com - Investing.com South Africa
RDHL appeals Nasdaq notice; 180-day extension possible - Stock Titan
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Benzinga
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Barchart.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire
CID Holdco Inc (DAIC): What Does Valuation Ratios Tell Us? - fostersleader.com
Lixte Biotechnology Holdings Inc (LIXT): What Technical Indicators Show - fostersleader.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - Sahm
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com South Africa
Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - Sahm
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PR Newswire
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - Finansavisen
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com India
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PR Newswire
Talicia® Launched in the United Arab Emirates - PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - Benzinga
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert!
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates - PR Newswire
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans - Stock Titan
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
REDHILL BIOPHAR/S ADR (NASDAQ:RDHL) had its Buy rating reiterated by HC Wainwright - marketexclusive.com
Technical Analysis of RedHill Biopharma Ltd. Sponsored ADR (NASDAQ:RDHL) - TradingView
RDHL Stock Price and Chart — NASDAQ:RDHL - TradingView
S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? - Insider Monkey
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Azioni (RDHL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.35%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):